Cardiol Therapeutics/$CRDL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cardiol Therapeutics
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Ticker
$CRDL
Sector
Primary listing
Employees
18
Headquarters
Oakville, Canada
Website
CRDL Metrics
BasicAdvanced
$111M
-
-$0.31
0.84
-
Price and volume
Market cap
$111M
Beta
0.84
52-week high
$1.59
52-week low
$0.77
Average daily volume
369K
Financial strength
Current ratio
3.893
Quick ratio
3.593
Long term debt to equity
1.017
Total debt to equity
1.404
Profitability
EBITDA (TTM)
-26.613
Management effectiveness
Return on assets (TTM)
-148.83%
Return on equity (TTM)
-347.98%
Valuation
Price to book
12.53
Price to tangible book (TTM)
12.53
Price to free cash flow (TTM)
-4.684
Free cash flow yield (TTM)
-21.35%
Free cash flow per share (TTM)
-0.215
Growth
Earnings per share change (TTM)
-21.04%
3-year earnings per share growth (CAGR)
-5.07%
What the Analysts think about CRDL
Analyst ratings (Buy, Hold, Sell) for Cardiol Therapeutics stock.
CRDL Financial Performance
Revenues and expenses
CRDL Earnings Performance
Company profitability
CRDL News
AllArticlesVideos
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
Newsfile Corp·6 hours ago
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure
Newsfile Corp·2 weeks ago
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cardiol Therapeutics stock?
Cardiol Therapeutics (CRDL) has a market cap of $111M as of February 25, 2026.
What is the P/E ratio for Cardiol Therapeutics stock?
The price to earnings (P/E) ratio for Cardiol Therapeutics (CRDL) stock is 0 as of February 25, 2026.
Does Cardiol Therapeutics stock pay dividends?
No, Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders as of February 25, 2026.
When is the next Cardiol Therapeutics dividend payment date?
Cardiol Therapeutics (CRDL) stock does not pay dividends to its shareholders.
What is the beta indicator for Cardiol Therapeutics?
Cardiol Therapeutics (CRDL) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.